<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03270514</url>
  </required_header>
  <id_info>
    <org_study_id>PRO17060305</org_study_id>
    <nct_id>NCT03270514</nct_id>
  </id_info>
  <brief_title>Comparison of Sternal Wound Infiltration With Liposomal Bupivacaine v. Bupivacaine Hydrochloride</brief_title>
  <official_title>Postoperative Analgesia After Cardiac Surgery - A Double-Blind, Prospective and Randomized Comparison of Wound Infiltration With Liposomal Bupivacaine and Bupivacaine Hydrochloride</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kathirvel Subramaniam</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pacira Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the analgesic efficacy and safety of wound infiltration
      with liposomal bupivacaine (LB) in patients undergoing cardiac surgery with sternotomy and
      cardiopulmonary bypass (CPB) and compare it with bupivacaine hydrochloride infiltration
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are no studies to date on the use of LB infiltration and its analgesic efficacy in
      cardiac surgery done through sternotomy, even though the majority of cardiac surgeries
      utilize this approach. Moderate to severe pain is common in patients undergoing these
      surgeries and is usually inadequately treated. Other various pain treatment modalities such
      as opioid and neuraxial anesthesia are avoided due to potentially dangerous side effects in
      this cohort. The efficacy of local anesthesia techniques, such as bupivacaine, are limited
      due to short duration of action and increased incidence of wound infection. On the other
      hand, slow release liposomal bupivacaine may last up to 72 hours, indicating it's potential
      for more adequate analgesia compared to bupivacaine.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 15, 2018</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Paticipant, care provider, investigator, and outcomes assessor are all blinded to the treatment allocation in double-blind fashion</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative Pain Intensity</measure>
    <time_frame>NRS scores will be evaluated every 4 hours until 24 hours post-operatively, every 8 hours until 48 hours post-operatively, and every 12 hours for 72 hours post-operatively</time_frame>
    <description>Postoperative pain scores evaluated by numeric rating scale or (NRS) where 0- no pain and 10- worst pain, at rest, deep inspiration or cough and at movement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Narcotic Consumption</measure>
    <time_frame>0-72 hours post-operative period</time_frame>
    <description>All narcotics administered in the first 72 hours (PCA narcotics, nurse-administered IV narcotics, and oral narcotics). All narcotics will be converted to total IV morphine equivalent for comparison between two groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Extubation</measure>
    <time_frame>From the end of surgery until the patient is extubated up to 72 hours post-operatively</time_frame>
    <description>The time it takes until the patient is extubated post-operatively will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Mobilization</measure>
    <time_frame>From time of end of surgery to time of mobilization up to 72 hours post-operatively</time_frame>
    <description>The time it takes until patient ambulates will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Out of Bed to Chair</measure>
    <time_frame>From time of end of surgery to time of mobilization up to 72 hours post-operatively</time_frame>
    <description>The time it takes until the patient advances from bedrest to out of bed (OOB) to chair will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Oral Intake</measure>
    <time_frame>rom time of end of surgery to time of oral intake up to 72 hours post-operatively</time_frame>
    <description>The time it takes until the patient is able to/medically cleared to consume food or liquid will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-invasive ventilation (NIV) requirement</measure>
    <time_frame>From time of end of surgery to 72 hours post-operatively</time_frame>
    <description>Episodes of NIV such as upper airway masks or similar devices will be quantified</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-intubation</measure>
    <time_frame>From time of end of surgery to patient discharge up to one week</time_frame>
    <description>Instances of re-intubation will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Incentive Spirometry</measure>
    <time_frame>From time of end of surgery to 72 hours post-operatively</time_frame>
    <description>Frequency of incentive spirometry will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative nausea and vomiting</measure>
    <time_frame>From time of end of surgery to 72 hours post-operatively</time_frame>
    <description>Frequency of nausea and emesis will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major organ dysfunction</measure>
    <time_frame>From date of surgery assessed up to 30 day post-operatively</time_frame>
    <description>Organ systems such as cardiac, renal, respiratory, and nervous system failure/dysfunction in accordance with the Society of Thoracic Surgeon's database will be noted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital and ICU Stay</measure>
    <time_frame>From date of surgery assessed up to 30 day post-operatively</time_frame>
    <description>Length of both hospital and ICU stay will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital readmission</measure>
    <time_frame>From end of surgery assessed up to 30 days post-operatively</time_frame>
    <description>Readmission to hospital will be noted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>From end of surgery assessed up to 30 days post-operatively</time_frame>
    <description>Mortality will be noted at specific timepoints</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Delirium</measure>
    <time_frame>Assessment will be administered at screening, 48 and 72 hours post-operatively</time_frame>
    <description>Patients will be assessed for delirium using the Intensive Care Delirium Screening Checklist (ICDSC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>Given at the time of discharge up to 30 days post-operatively</time_frame>
    <description>Patient will give an assessment regarding pain management</description>
  </other_outcome>
  <other_outcome>
    <measure>Chronic Pain Assessment</measure>
    <time_frame>6 and 12 months after surgery</time_frame>
    <description>Subjects will be asked: On a scale of 0 to 10, with 0 being no pain at all and 10 being the worst pain imaginable, how would you rate your pain? Current, worst and best pain levels will be questioned and an average pain score will be taken during rest and activity</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum Cortisol levels</measure>
    <time_frame>Measured 8, 48, and 72 hours post-operatively</time_frame>
    <description>Stress response suppression as a result of treatment will be evaluated by comparing hormone levels between the groups. Serum cortisol levels will be taken to measure this.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">117</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Artery Stenoses</condition>
  <condition>Valve Regurgitation, Mitral</condition>
  <condition>Valve Regurgitation, Tricuspid</condition>
  <arm_group>
    <arm_group_label>Exparel Injectable Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liposomal Bupivacaine Injection administered approximately 20 cc per inch of sternotomy wound. Half of subjects enrolled will be randomized to the LB group (~59).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine Hydrochloride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupivacaine Injection administered approximately 20 cc per inch of sternotomy wound. Half of subjects enrolled will be randomized to the bupivacaine group (~59).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exparel Injectable Product</intervention_name>
    <description>Liposomal bupivacaine 20 cc (226 mg) + Bupivacaine Hydrochloride 0.25% 40 cc (100 mg) + made up to calculated volume with normal saline solution based on the length of the incision and number of chest tubes (20 cc per tube + 20cc per inch of incision)</description>
    <arm_group_label>Exparel Injectable Product</arm_group_label>
    <other_name>Liposomal Bupivacaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine Hydrochloride</intervention_name>
    <description>Bupivacaine 0.25% 2 mg/kg not to exceed 150 mg - made up to made up to calculated volume with normal saline solution based on the length of the incision and number of chest tubes (20 cc per tube + 20cc per inch of incision)</description>
    <arm_group_label>Bupivacaine Hydrochloride</arm_group_label>
    <other_name>Bupivacaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Open cardiac surgery through sternotomy approach (coronary artery bypass as well as
             other open cardiac procedures)

          -  Surgery with the use of cardiopulmonary bypass

        Exclusion Criteria:

          -  Minimally invasive heart surgery through thoracotomy approach

          -  Patient undergoing procedures under deep hypothermic circulatory arrest

          -  Patients with active infections such as infective endocarditis

          -  Emergency surgery

          -  Patients undergoing transplantations and ventricular assist device insertion

          -  Patients on any mechanical circulatory support preoperatively

          -  Patient's refusal

          -  End stage liver or renal disease

          -  Allergy to bupivacaine

          -  Patient who cannot understand the study procedure or refuse to participate

          -  Redo-sternotomy

          -  Participation in another study

          -  Patients with severe right or left ventricular dysfunction (EF&lt; 25%)

          -  Patients requiring chronic opioids for chronic pain condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathirvel Subramaniam, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor and staff Anesthesiologist</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy Monroe</last_name>
    <phone>412-623-6382</phone>
    <email>monroeal@upmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeana Tiskiewicz</last_name>
    <phone>412-623-2640</phone>
    <email>tiskiewiczj@upmc.edu</email>
  </overall_contact_backup>
  <reference>
    <citation>Bigeleisen PE, Goehner N. Novel approaches in pain management in cardiac surgery. Curr Opin Anaesthesiol. 2015 Feb;28(1):89-94. doi: 10.1097/ACO.0000000000000147. Review.</citation>
    <PMID>25500688</PMID>
  </reference>
  <reference>
    <citation>Sun XL, Zhao ZH, Ma JX, Li FB, Li YJ, Meng XM, Ma XL. Continuous Local Infiltration Analgesia for Pain Control After Total Knee Arthroplasty: A Meta-analysis of Randomized Controlled Trials. Medicine (Baltimore). 2015 Nov;94(45):e2005. doi: 10.1097/MD.0000000000002005. Review.</citation>
    <PMID>26559294</PMID>
  </reference>
  <reference>
    <citation>Tong YC, Kaye AD, Urman RD. Liposomal bupivacaine and clinical outcomes. Best Pract Res Clin Anaesthesiol. 2014 Mar;28(1):15-27. doi: 10.1016/j.bpa.2014.02.001. Epub 2014 Mar 15. Review.</citation>
    <PMID>24815964</PMID>
  </reference>
  <reference>
    <citation>Kalogera E, Bakkum-Gamez JN, Weaver AL, Moriarty JP, Borah BJ, Langstraat CL, Jankowski CJ, Lovely JK, Cliby WA, Dowdy SC. Abdominal Incision Injection of Liposomal Bupivacaine and Opioid Use After Laparotomy for Gynecologic Malignancies. Obstet Gynecol. 2016 Nov;128(5):1009-1017.</citation>
    <PMID>27741199</PMID>
  </reference>
  <reference>
    <citation>Hutchins JL, Kesha R, Blanco F, Dunn T, Hochhalter R. Ultrasound-guided subcostal transversus abdominis plane blocks with liposomal bupivacaine vs. non-liposomal bupivacaine for postoperative pain control after laparoscopic hand-assisted donor nephrectomy: a prospective randomised observer-blinded study. Anaesthesia. 2016 Aug;71(8):930-7. doi: 10.1111/anae.13502. Epub 2016 May 30.</citation>
    <PMID>27238859</PMID>
  </reference>
  <reference>
    <citation>Hutchins J, Delaney D, Vogel RI, Ghebre RG, Downs LS Jr, Carson L, Mullany S, Teoh D, Geller MA. Ultrasound guided subcostal transversus abdominis plane (TAP) infiltration with liposomal bupivacaine for patients undergoing robotic assisted hysterectomy: A prospective randomized controlled study. Gynecol Oncol. 2015 Sep;138(3):609-13. doi: 10.1016/j.ygyno.2015.06.008. Epub 2015 Jun 6.</citation>
    <PMID>26056753</PMID>
  </reference>
  <reference>
    <citation>Beck DE, Margolin DA, Babin SF, Russo CT. Benefits of a Multimodal Regimen for Postsurgical Pain Management in Colorectal Surgery. Ochsner J. 2015 Winter;15(4):408-12.</citation>
    <PMID>26730224</PMID>
  </reference>
  <reference>
    <citation>Knudson RA, Dunlavy PW, Franko J, Raman SR, Kraemer SR. Effectiveness of Liposomal Bupivacaine in Colorectal Surgery: A Pragmatic Nonsponsored Prospective Randomized Double Blinded Trial in a Community Hospital. Dis Colon Rectum. 2016 Sep;59(9):862-9. doi: 10.1097/DCR.0000000000000648.</citation>
    <PMID>27505115</PMID>
  </reference>
  <reference>
    <citation>Ayad S, Babazade R, Elsharkawy H, Nadar V, Lokhande C, Makarova N, Khanna R, Sessler DI, Turan A. Comparison of Transversus Abdominis Plane Infiltration with Liposomal Bupivacaine versus Continuous Epidural Analgesia versus Intravenous Opioid Analgesia. PLoS One. 2016 Apr 15;11(4):e0153675. doi: 10.1371/journal.pone.0153675. eCollection 2016. Erratum in: PLoS One. 2016;11(9):e0163687.</citation>
    <PMID>27082959</PMID>
  </reference>
  <reference>
    <citation>Knight RB, Walker PW, Keegan KA, Overholser SM, Baumgartner TS, Ebertowski JS 2nd, Aden JK, White MA. A Randomized Controlled Trial for Pain Control in Laparoscopic Urologic Surgery: 0.25% Bupivacaine Versus Long-Acting Liposomal Bupivacaine. J Endourol. 2015 Sep;29(9):1019-24. doi: 10.1089/end.2014.0769. Epub 2015 Jun 5.</citation>
    <PMID>25897552</PMID>
  </reference>
  <reference>
    <citation>Routman HD, Israel LR, Moor MA, Boltuch AD. Local injection of liposomal bupivacaine combined with intravenous dexamethasone reduces postoperative pain and hospital stay after shoulder arthroplasty. J Shoulder Elbow Surg. 2017 Apr;26(4):641-647. doi: 10.1016/j.jse.2016.09.033. Epub 2016 Nov 15.</citation>
    <PMID>27856266</PMID>
  </reference>
  <reference>
    <citation>Okoroha KR, Lynch JR, Keller RA, Korona J, Amato C, Rill B, Kolowich PA, Muh SJ. Liposomal bupivacaine versus interscalene nerve block for pain control after shoulder arthroplasty: a prospective randomized trial. J Shoulder Elbow Surg. 2016 Nov;25(11):1742-1748. doi: 10.1016/j.jse.2016.05.007. Epub 2016 Jul 14.</citation>
    <PMID>27422692</PMID>
  </reference>
  <reference>
    <citation>Kuang MJ, Du Y, Ma JX, He W, Fu L, Ma XL. The Efficacy of Liposomal Bupivacaine Using Periarticular Injection in Total Knee Arthroplasty: A Systematic Review and Meta-Analysis. J Arthroplasty. 2017 Apr;32(4):1395-1402. doi: 10.1016/j.arth.2016.12.025. Epub 2016 Dec 23. Review.</citation>
    <PMID>28082044</PMID>
  </reference>
  <reference>
    <citation>Ma J, Zhang W, Yao S. Liposomal bupivacaine infiltration versus femoral nerve block for pain control in total knee arthroplasty: A systematic review and meta-analysis. Int J Surg. 2016 Dec;36(Pt A):44-55. doi: 10.1016/j.ijsu.2016.10.007. Epub 2016 Oct 11. Review.</citation>
    <PMID>27742564</PMID>
  </reference>
  <reference>
    <citation>Yu SW, Szulc AL, Walton SL, Davidovitch RI, Bosco JA, Iorio R. Liposomal Bupivacaine as an Adjunct to Postoperative Pain Control in Total Hip Arthroplasty. J Arthroplasty. 2016 Jul;31(7):1510-5. doi: 10.1016/j.arth.2016.01.004. Epub 2016 Jan 21.</citation>
    <PMID>26872584</PMID>
  </reference>
  <reference>
    <citation>Cherian JJ, Barrington J, Elmallah RK, Chughtai M, Mistry JB, Mont MA. Liposomal Bupivacaine Suspension, Can Reduce Length of Stay and Improve Discharge Status of Patients Undergoing Total Hip Arthroplasty. Surg Technol Int. 2015 Nov;27:235-9.</citation>
    <PMID>26680403</PMID>
  </reference>
  <reference>
    <citation>Barrington JW, Olugbode O, Lovald S, Ong K, Watson H, Emerson RH Jr. Liposomal Bupivacaine: A Comparative Study of More Than 1000 Total Joint Arthroplasty Cases. Orthop Clin North Am. 2015 Oct;46(4):469-77. doi: 10.1016/j.ocl.2015.06.003. Epub 2015 Aug 6. Review.</citation>
    <PMID>26410636</PMID>
  </reference>
  <reference>
    <citation>Barrington JW, Halaszynski TM, Sinatra RS, Expert Working Group On Anesthesia And Orthopaedics Critical Issues In Hip And Knee Replacement Arthroplasty FT. Perioperative pain management in hip and knee replacement surgery. Am J Orthop (Belle Mead NJ). 2014 Apr;43(4 Suppl):S1-S16.</citation>
    <PMID>24911869</PMID>
  </reference>
  <reference>
    <citation>Kim J, Burke SM, Kryzanski JT, Roberts RJ, Roguski M, Qu E, Hwang SW, Liu PP, Desilier A, Riesenburger RI. The Role of Liposomal Bupivacaine in Reduction of Postoperative Pain After Transforaminal Lumbar Interbody Fusion: A Clinical Study. World Neurosurg. 2016 Jul;91:460-7. doi: 10.1016/j.wneu.2016.04.058. Epub 2016 Apr 22.</citation>
    <PMID>27113396</PMID>
  </reference>
  <reference>
    <citation>Grieff AN, Ghobrial GM, Jallo J. Use of liposomal bupivacaine in the postoperative management of posterior spinal decompression. J Neurosurg Spine. 2016 Jul;25(1):88-93. doi: 10.3171/2015.11.SPINE15957. Epub 2016 Mar 4.</citation>
    <PMID>26943250</PMID>
  </reference>
  <reference>
    <citation>Abdelsattar JM, Boughey JC, Fahy AS, Jakub JW, Farley DR, Hieken TJ, Degnim AC, Goede W, Mohan AT, Harmsen WS, Niesen AD, Tran NV, Bakri K, Jacobson SR, Lemaine V, Saint-Cyr M. Comparative Study of Liposomal Bupivacaine Versus Paravertebral Block for Pain Control Following Mastectomy with Immediate Tissue Expander Reconstruction. Ann Surg Oncol. 2016 Feb;23(2):465-70. doi: 10.1245/s10434-015-4833-4. Epub 2015 Aug 26.</citation>
    <PMID>26307232</PMID>
  </reference>
  <reference>
    <citation>Smoot JD, Bergese SD, Onel E, Williams HT, Hedden W. The efficacy and safety of DepoFoam bupivacaine in patients undergoing bilateral, cosmetic, submuscular augmentation mammaplasty: a randomized, double-blind, active-control study. Aesthet Surg J. 2012 Jan;32(1):69-76. doi: 10.1177/1090820X11430831. Epub 2011 Dec 16.</citation>
    <PMID>22179931</PMID>
  </reference>
  <reference>
    <citation>Oppenheimer AJ, Fiala TGS, Oppenheimer DC. Direct Transversus Abdominis Plane Blocks With Exparel During Abdominoplasty. Ann Plast Surg. 2016 Nov;77(5):499-500. doi: 10.1097/SAP.0000000000000659.</citation>
    <PMID>26545224</PMID>
  </reference>
  <reference>
    <citation>Morales R Jr, Mentz H 3rd, Newall G, Patronella C, Masters O 3rd. Use of abdominal field block injections with liposomal bupivicaine to control postoperative pain after abdominoplasty. Aesthet Surg J. 2013 Nov 1;33(8):1148-53. doi: 10.1177/1090820X13510720. Epub 2013 Nov 8.</citation>
    <PMID>24214950</PMID>
  </reference>
  <reference>
    <citation>Golf M, Daniels SE, Onel E. A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy. Adv Ther. 2011 Sep;28(9):776-88. doi: 10.1007/s12325-011-0052-y. Epub 2011 Aug 12.</citation>
    <PMID>21842428</PMID>
  </reference>
  <reference>
    <citation>Vyas KS, Rajendran S, Morrison SD, Shakir A, Mardini S, Lemaine V, Nahabedian MY, Baker SB, Rinker BD, Vasconez HC. Systematic Review of Liposomal Bupivacaine (Exparel) for Postoperative Analgesia. Plast Reconstr Surg. 2016 Oct;138(4):748e-56e. doi: 10.1097/PRS.0000000000002547. Review.</citation>
    <PMID>27673545</PMID>
  </reference>
  <reference>
    <citation>Khalil KG, Boutrous ML, Irani AD, Miller CC 3rd, Pawelek TR, Estrera AL, Safi HJ. Operative Intercostal Nerve Blocks With Long-Acting Bupivacaine Liposome for Pain Control After Thoracotomy. Ann Thorac Surg. 2015 Dec;100(6):2013-8. doi: 10.1016/j.athoracsur.2015.08.017. Epub 2015 Oct 24.</citation>
    <PMID>26507422</PMID>
  </reference>
  <reference>
    <citation>Balkhy HH, Arnsdorf S, Krienbring D, Urban J. Liposome Bupivacaine for Postsurgical Analgesia in Patients Undergoing Robotically Assisted Cardiac Surgery. Innovations (Phila). 2015 Nov-Dec;10(6):416-9. doi: 10.1097/IMI.0000000000000190.</citation>
    <PMID>26633002</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2017</study_first_submitted>
  <study_first_submitted_qc>August 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2017</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Kathirvel Subramaniam</investigator_full_name>
    <investigator_title>Principal Investigator, Associate Professor</investigator_title>
  </responsible_party>
  <keyword>cardiac surgery</keyword>
  <keyword>sternotomy</keyword>
  <keyword>post-operative pain</keyword>
  <keyword>sternal wound infiltration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

